Drug Sponsors

Sartorius acquires Umetrics, closes acquisition of Essen BioScience

Tuesday, April 11, 2017

Sartorius, an international partner of the biopharmaceutical industry and research laboratories, acquired through its subgroup Sartorius Stedim Biotech the company MKS Instruments (Umetrics) based in Malmö, Sweden. Umetrics is a specialist in data analytics software for modeling and optimizing biopharmaceutical development and manufacturing processes. Umetrics has already been cooperating with Sartorius for around five years and, in 2017, plans to generate full-year sales revenue of around U.S. $15 million and a significant double-digit operating profit margin. Sartorius purchased the company for U.S. $72.5 million from the U.S. MKS Instruments Group.

[Read More]

i2b2 Foundation, Transmart Foundation to merge

Friday, April 7, 2017

Two open-source foundations, the tranSMART Foundation and the Informatics for Integrating Biology and the Bedside (i2b2 Foundation), in the healthcare and translational research space are merging into a single foundation to advance the field of precision medicine. These organizations provide open-source software and databases representing more than 100 million patient lives to thousands of physicians and scientists worldwide.

[Read More]

Sucampo acquires Vtesse

Tuesday, April 4, 2017

Sucampo Pharmaceuticals, a global biopharmaceutical company, has acquired Vtesse, a privately held rare disease company, for upfront consideration of $200 million. Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand; no external financing was utilized. 

[Read More]

BioLineRx acquires Agalimmune to accelerate immuno-oncology pipeline

Thursday, March 23, 2017

BioLineRx, a clinical-stage biopharmaceutical company focused on oncology and immunology, has acquired Agalimmune, a private U.K.-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of which $3 million is in cash and the remainder in BioLineRx shares. Additional future payments may be made based on development and commercial milestones.

[Read More]

Califf launches People-Centered Clinical Research Foundation

Wednesday, March 22, 2017

Dr. Robert Califf has launched the People-Centered Research Foundation (PCRF), a new nonprofit organization committed to accelerating people-driven research. PCRF has been created to sustain and expand a national network for clinical research that originated with funding from the Patient-Centered Outcomes Research Institute (PCORI) and studies conducted by the National Patient-Centered Clinical Research Network (PCORnet).

[Read More]

Boston Biomedical Associates creates Boston Biomedical Associates Limited Tel Aviv

Wednesday, March 15, 2017

Boston Biomedical Associates (BBA), a clinical research and consulting company based in Marlborough, Massachusetts, has announced the opening of an affiliate office, Boston Biomedical Associates Limited (BBA Ltd.) in Tel Aviv, Israel. Tami Abudi and Adi Richter have been named co-chief executive officers of Boston Biomedical Associates Limited. Abudi also serves as the director of Clinical Development and Adi Richter as the director of Legal Affairs.

[Read More]

Virta Health launches in the Bay Area with $37M

Monday, March 13, 2017

Virta Health, a new company founded by a team of physicians, scientists and technologists trained at Stanford, MIT and Harvard, launched with a bold mission to reverse type 2 diabetes—a chronic, progressive condition that affects more than 29 million Americans and 415 million people globally. The company’s debut comes on the heels of a new peer-reviewed study that demonstrates Virta was successful in reversing type 2 diabetes in half of its clinical trial patients and eliminating or reducing insulin in 87% of patients in just 10 weeks.

[Read More]